

2-2017

## miRNA nanotherapeutics for cancer

Aditya Ganju

Sheema Khan

*The University of Texas Rio Grande Valley, sheema.khan@utrgv.edu*

Bilal B. Hafeez

*The University of Texas Rio Grande Valley*

Stephen Behrman

Murali M. Yallapu

*The University of Texas Rio Grande Valley, murali.yallapu@utrgv.edu*

*See next page for additional authors*

Follow this and additional works at: [https://scholarworks.utrgv.edu/som\\_pub](https://scholarworks.utrgv.edu/som_pub)



Part of the [Medicine and Health Sciences Commons](#)

---

### Recommended Citation

Ganju, A., Khan, S., Hafeez, B. B., Behrman, S. W., Yallapu, M. M., Chauhan, S. C., & Jaggi, M. (2017). miRNA nanotherapeutics for cancer. *Drug discovery today*, 22(2), 424–432. <https://doi.org/10.1016/j.drudis.2016.10.014>

This Article is brought to you for free and open access by the School of Medicine at ScholarWorks @ UTRGV. It has been accepted for inclusion in School of Medicine Publications and Presentations by an authorized administrator of ScholarWorks @ UTRGV. For more information, please contact [justin.white@utrgv.edu](mailto:justin.white@utrgv.edu), [william.flores01@utrgv.edu](mailto:william.flores01@utrgv.edu).

---

**Authors**

Aditya Ganju, Sheema Khan, Bilal B. Hafeez, Stephen Behrman, Murali M. Yallapu, Subhash C. Chauhan, and Meena Jaggi



Published in final edited form as:

*Drug Discov Today*. 2017 February ; 22(2): 424–432. doi:10.1016/j.drudis.2016.10.014.

## miRNA nanotherapeutics for cancer

Aditya Ganju<sup>1</sup>, Sheema Khan<sup>1</sup>, Bilal B. Hafeez<sup>1</sup>, Stephen W. Behrman<sup>2</sup>, Murali M. Yallapu<sup>1</sup>, Subhash C. Chauhan<sup>1</sup>, and Meena Jaggi<sup>1</sup>

<sup>1</sup>Department of Pharmaceutical Sciences and the Center for Cancer Research, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN 38163, USA

<sup>2</sup>Department of Surgery, University of Tennessee Health Science Center, Memphis, TN 38163, USA

### Abstract

miRNAs are noncoding RNA molecules that regulate gene expression through diverse mechanisms. Increasing evidence suggests that miRNA-based therapies, either restoring or repressing miRNA expression and activity, hold great promise. However, the efficient delivery of miRNAs to target tissues is a major challenge in the transition of miRNA therapy to the clinic. Cationic polymers or viral vectors are efficient delivery agents but their systemic toxicity and immunogenicity limit their clinical usage. Efficient targeting and sustained release of miRNAs/anti-miRNAs using nanoparticles (NPs) conjugated with antibodies and/or peptides could reduce the required therapeutic dosage while minimizing systemic and cellular toxicity. Given their importance in clinical oncology, here we focus on the development of miRNA nanoformulations to achieve enhanced cellular uptake, bioavailability, and accumulation at the tumor site.

### Keywords

miRNAs; tumor suppressors; oncogenic; nanotechnology; non-viral delivery; liposome; cationic polymers

### Introduction

miRNAs are 22 nucleotide-long, noncoding RNA molecules that act as negative regulators of gene expression and regulate a range of biological functions, including cell survival, proliferation, apoptosis, tumor growth, and metastasis [1]. miRNAs bind to a complimentary mRNA sequence and result in post-translation repression or degradation and silencing. miRNAs are formed by transcription of RNA polymerase II, which folds back to form a distinctive hairpin structure, whereas other small mRNAs are formed from longer hairpin

---

*Corresponding authors:* Jaggi, M. (mjaggi@uthsc.edu); Chauhan, S.C. (schauha1@uthsc.edu); Yallapu, M.M. (myallapu@uthsc.edu).

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

*Teaser:* miRNA-based therapy is a promising new avenue in cancer therapeutics. However, delivery of miRNA to cancer cells is a challenge. Herein, we discuss various nanotechnology-based delivery options for miRNA.

structures [2]. Processing of miRNAs as primary (pri)-miRNA and pre-miRNA (in the nucleus); mature miRNA duplexes, RNA-induced silencing complex (RISC) strand-mediated complex, and complementary mRNA sequence formation cause translation repression and mRNA degradation (in the cytoplasm) [3,4].

miRNAs have significant roles in cancer, as evident from the more than 25 000 peer-reviewed reports (Figure 1A) and clinical studies on this topic over the years. Although several miRNAs modulating carcinogenic processes have been identified, their clinical translation is limited because of their unsuccessful delivery at the tumor site and their broad functionality, which results in off-target effects. Lentiviral vectors have shown efficient cellular delivery, but their activation of oncogenes and/or excessive immunogenicity raise concerns over the safety of genomic integration. To overcome such limitations, nonviral miRNA delivery systems, such as polyethyleneimine (PEI)-based NPs, liposomes, polymeric micelles, dendrimers, magnetic NPs, and polymeric NPs (Figure 1B), have been proposed. These delivery systems protect the degradation of miRNAs by nucleases and increase their half-life in the blood [5], can escape from endosomal and/or lysosomal degradation, and deliver miRNAs to the cytoplasm or nucleus (Figure 1C). The first miRNA replacement therapy to enter clinical trials involved the restitution of a tumor suppressor miRNA (miR-34) in modified liposomes (MRX34, Mirna Therapeutics; [www.mirnatherapeutics.com/pipeline/mirna-MRX34.html](http://www.mirnatherapeutics.com/pipeline/mirna-MRX34.html)). MRX34 showed promising results in a Phase I clinical trial, where partial responses were observed in patients with renal cell carcinoma (RCC), acral melanoma, or hepatocellular carcinoma. Many patients with advanced-stage disease showed promising results while on treatment. Thus, the company plans to start two Phase 2 trials with MRX34 for patients with RCC and melanoma by the end of 2016. Given the clinical impact of miRNAs in cancer, we review here the strategies implemented for the delivery of tumor suppressor miRNAs or anti-miRNAs using nanotechnology-based formulations for the treatment of various types of cancer.

## Delivery of miRNAs: major obstacles and nanotechnology

Although accumulating scientific evidences proves that the role of miRNAs is significant in cancer, translation into clinical applications has several issues. The main reasons include poor systemic stability, rapid clearance, and lack of efficient delivery. In general, oligonucleotides in the bloodstream have a half-life of a couple of minutes; however, suitable substitution can improve the half-life to several hours [6]. The kidney is one of the barriers that readily accumulates and clears oligonucleotides from the body via renal clearance. The liver is another organ that abundantly takes up these oligonucleotides for clearance from the body [6]. The other major barrier is the reticuloendothelial system (RES), in which Kupffer cells of liver and spleen macrophages eliminate these oligonucleotides from the circulation system. Phagocytosis of the oligonucleotide results in a phagosome, which is then integrated into the lysosome, where it is degraded by nucleases [6]. Nuclease activity in plasma and tissue degrade the oligonucleotide very rapidly. This phenomenon can be avoided by targeted delivery of NPs to cancer cells [7]. Nanocarrier-mediated oligonucleotide delivery is capable of crossing endothelial cells into the interstitial space of the tumor [6]. In addition, oligonucleotides can be delivered into the cytoplasm for translation via endocytosis using a nanocarrier that can escape endosomal degradation.

There are many NPs or nanocarriers being used to deliver miRNAs, each uniquely formulated and with distinctive composition.

One of the most widely used groups of polymers for the delivery of nucleic acids to cells are cationic polymers, because, being positively charged, these can be conjugated to the negatively charged nucleic acids. They also present low toxicity and low immunogenic responses compared with other polymer-based systems for gene delivery [8]. Cationic polymers are subdivided into naturally derived and synthetically derived polymers. Naturally derived cationic polymers include chitosan (CS), dextran, gelatin, cellulose, and cyclodextrin polymer, whereas synthetically derived cationic polymers include PEI, poly(*L*-Lysine), poly(amido amines), poly(amino-*co*-ester), poly-(2-*N,N*-dimethylaminoethylmethacrylate), and dendrimers, of which PEI and its conjugates have been widely exploited for gene delivery purposes [8]. Low-molecular-weight PEI polymers are considered to be efficient carriers for the delivery of small nucleic acids, miRNAs, and small interfering (si)RNAs because of their low toxicity compared with other transfection agents [9]. The main advantage of the PEI-based delivery system is the rapid uptake and release ('proton sponge effect') (Figure 1C) of the nucleic acid inside the cell via an endocytic mechanism [9]. Schade *et al.* [10] showed that the combination of PEI with a magnetic NP formulation led to efficient delivery of the nucleic acid to target cells. Quantum dots (QDs) conjugated to PEI can enhance theranostic applications to provide imaging, gene delivery, and cellular labeling [11]. However, limitations associated with the PEI delivery system include poorer biodegradability inside the cell, leading to its accumulation and cytotoxicity [12]. Therefore, new research leading to improved PEI-based delivery systems is needed.

Liposomes are amphiphilic molecules that comprise phospholipids, are biocompatible and biodegradable, and, to a great extent, resemble the cell membrane of a human cell [13]. Given their resemblance to the cell membrane bilayer, liposomes have a tendency to pass through cell membranes and release their encapsulated payloads (i.e., miRNAs). The issues of low sensitivity or specificity and toxicity [13] can be overcome by surface modification, as detailed in Table 1. Polymeric micelles, which are highly soluble in water, have been largely identified as suitable carriers for, and distributors of, anticancer drug(s). These micelles have an outer and inner core that determine the different physicochemical properties of these nanocarriers [14]; for example, their surface composition, hydrophobicity, and crystallinity [14] determine the payload release. NPs comprising polymers, lipids, hybrids, and metal/metal oxides provide significant opportunities for targeted delivery [15]. NPs readily accumulate at tumor sites because of an 'enhanced permeability and retention' effect [16].

Here, we discuss various novel strategies to circumvent antisense targeting and delivery to cancer cells through the use of nanotechnology.

## Using nanotechnology formulations to deliver miRNAs to tumors

### Breast cancer

miRNA nanoformulations targeting hyaluronic acid (HA) receptors, which are overexpressed in breast cancer, is a novel approach. A recent study showed that HA-CS NPs

efficiently delivered tumor suppressor miR-34a and doxorubicin (Dox) to breast cancer cell-derived xenograft tumors in athymic nude mice, resulting in the increased inhibition of tumor growth and tumor volume compared with Dox-NPs or free Dox [17]. HA-CS-coated PEI-poly(D,L-lactide-co-glycolide) (PEI-PLGA) NPs conjugated with dox and miR-542-3p both improved targeting and increased the uptake of NPs in triple-negative breast cancer cells [18]. Furthermore, delivery of PLGA-PEG NPs encapsulating antisense-miR-21 and orlistat or orlistat NP in combination with Dox significantly enhanced apoptotic effects in MDA-MB-231 and SKBR-3 triple-negative breast cancer cells [19]. In another study, PLGA-*b*-PEG NPs were successful in delivering anti-sense miR-21 and miR-10b in triple-negative breast cancer [20]. A nanoporous silicon microparticle modified by arginine-PEI in combination with miR-18a has been used to target breast cancer cells and resulted in a 90% knockdown of *ATMK* (an miR-18a target gene) and a significant reduction in tumor volume in a murine model of MDA-MB-231 cells [21]. Another CS-based nanoformulation incorporating negatively charged poly( $\gamma$ -glutamic acid) (PGA) was conjugated with QD-miRNA let-7a-gold NP (QD-RNA-Au NP) for delivery to breast cancer cells where Dicer-mediated release of QD resulted in fluorescence, demonstrating its theranostic effectiveness [22]. Anti-miR-21 delivery with a PEI/poly(sodium 4-styrenesulfonates) (PSS)/grapheme oxide (GO) nanocomplex conjugated to adriamycin inhibited 40% of miR-21 and 45% of ABC transporter expression levels and resulted in a twofold increase in uptake of adriamycin [23]. In a recent study, intravenous injection of exosomes conjugated with epidermal growth factor (EGF) peptide targeting EGF receptor (EGFR)-expressing cells with encapsulated let-7a was shown to be effective in xenograft mouse models of breast cancer cells [24].

### Prostate cancer

Various miRNAs, including miR-34a, -21, and -153, have been implicated in prostate tumorigenesis [25]. A recent study demonstrated that the delivery of CS-encapsulated miR-34a intrafemorally reduced bone tumor growth and volume by twofold [26]. Exosomes have been shown to effectively deliver anti-miR-21 oligonucleotides to prostate cancer cells, leading to a significant downregulation of miR-21 levels and decreased motility of prostate cancer cells [27]. miR-34a delivery has shown chemosensitization of paclitaxel treatment in prostate cancer cells by targeting the Bcl-2 protein [28]. Let-7c miRNA, conjugated with a NP-based system targeted for prostate cancer cells using anti-prostate specific membrane antigen (PSMA) antibody or aptamer conjugation, showed enhanced targeting and uptake. Gold NPs formulated for the delivery of miRNAs into cancer cells showed a payload that was approximately 10–20 times higher than that of lipofectamine, lower toxicity, efficient uptake, fast endosomal[DE1], and increased half-live [29]. Introduction of disulfide linkage in PEI (SSPEI) led to better biocompatibility and reduced the associated toxicity, whereas delivery of polyarginine peptide (R11)-labeled SSPEI NP showed specific uptake in prostate cancer cells [30]. This strategy not only reduced toxicity, but also enhanced the restitution of the tumor suppressor miR-145 to prostate cancer, resulting in decreased tumor burden in xenografted mice.

### Pancreatic cancer

Deregulation of miRNAs has been shown in pancreatic cancer, leading to enhanced tumor growth and metastasis [31]. Various miRNAs, such as miR-221, -21, -375, -34a, and -145,

have been implicated in pancreatic carcinogenesis. miR-221 has been known to function as an oncogene by promoting the growth of pancreatic ductal adenocarcinoma (PDAC) by regulating the key oncogenic PTEN-AKT pathway [32] and increased expression of matrix metalloproteases (MMP), such as MMP-2 and MMP-9 [33]. miR-145 functions as a tumor suppressor in pancreatic cancer and is known to target Mucin 13 (MUC13) to inhibit pancreatic cancer growth and invasion [34]. A magnetic NP formulation encapsulating miR-145 efficiently delivered miR-145 to the tumor site and downregulated the expression of oncogenic signaling, such as MUC13, HER2, and pAKT, to inhibit pancreatic cancer growth and invasion [35]. NP-encapsulated delivery of miRNA for pancreatic cancer treatment remains an unexplored field that has potential therapeutic value. In a previous report, tumor suppressor miR-34a restitution was achieved using an antibody-modified liposome/polycation delivery system in a Panc-1 xenograft mouse model [21]. Gold NPs with fluorophore-labeled hairpin DNA, so-called 'gold nanobeacons', were used to target and silence miR-21, an endogenous miRNA involved in cancer development and chemoresistance [36]. The miR-375 expression level in pancreatic cancer is associated with the carcinogenesis of pancreatic cancer cells. A solid lipid NP delivery system in conjugation with miR-375 efficiently reached pancreatic tumors and inhibited pancreatic cancer growth *in vitro* and in *in vivo* models. The delivery of miR-150-encapsulated NPs increased the expression of miR-150 in Colo-357 and HPAF cells by 28- and 26-fold, respectively, compared with transfection of miRNA via lipofectamine [37].

### Ovarian cancer

The efficient delivery of anti-miR-21 to ovarian cancer cells has been observed to reduce the tumor initiation cell burden [38]. A recent study showed a gold NP delivery system for anti-miR-21 to be an excellent platform to target and silence miR-21 in ovarian cancer cells, inhibiting the sphere-forming capacity of tumor-initiating cells. miR-155 is downregulated in ovarian tumor-associated dendritic cells (DCs) and is essential for optimal antigen presentation and activation of T cells by DCs [39]. PEI-based nanocomplexes were used to deliver miR-155 to tumor-associated DC, which increased the expression of miR-155 *in vitro* and resulted in increased antitumor immunity and, thus, increased survival of the mice (by 65%) [39]. miR-124 is downregulated in ovarian cancer and acts as a tumor suppressor by targeting proteins such as myc and Rb and increasing the expression of p27, subsequently leading to cell cycle arrest at G1 phase because of the loss of phospho-Rb and decreased expression of the myc protein [40]. Transfection of miR-124 in an ovarian cancer cell line reduced the invasive and migratory capability of ovarian cancer cells and increased their sensitivity to etoposide by twofold. Another miR-124 miRNA, which acts as a tumor suppressor in ovarian cancer, modulating cell cycle-regulating genes, was efficiently restored in ovarian cancer cell xenograft tumors using 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) NPs. These DOPC NPs significantly restored miR-124 in tumors, resulting in a significant decrease in tumor weight alone or in combination with etoposide [40].

### Lung cancer

Recent studies demonstrated the feasibility of systemically delivering miRNA mimics and siRNAs simultaneously to lung adenocarcinoma cells using polymer-based NPs in a mouse model of lung cancer, eliciting a potent antitumor response. [41]. It was shown that miR-34a

acts as a tumor suppressor and is significantly downregulated in lung cancer [42]. miR-34a targets the p53 signaling pathway to regulate cell cycle progression and apoptosis induction in cancer cells [42]. Liposomes encapsulating miR-34a were effectively delivered to lung cancer cells to mediate the inhibition of cell cycle progression and activation of apoptosis in lung cancer cells, thereby causing a significant decrease in tumor cell growth and volume in an orthotopic mouse model of lung cancer [43]. miR-200c is a known negative regulator of ZEB1, which induces the epithelial–mesenchymal transition (EMT) in cancer cells [44]. Liposomal NP-encapsulated miR-200c delivered to lung cancer cells induced the activation of oxidative stress response genes and enhanced the radiosensitivity of lung cancer cells up to 1.5 times in an *in vivo* mice model [45]. Multifunctional aptamer conjugated to miRNA is another method of delivering tumor suppressor genes, such as *let7g*, to lung cancer cells, significantly reducing tumor volume compared with aptamer treatment alone [46]. miR-29b is downregulated in non-small cell lung cancer (NSCLC) cells and directly targets oncogene cyclin-dependent kinase 6 (CDK6) to regulate cell cycle progression in these cells [47,48]. Cationic lipoplex-based delivery of miR-29b to lung cancer cells effectively reduced CDK6 expression by almost 54% and reduced tumor volume by almost 50% *in vivo* [48].

### Brain cancer

Poly(amido amine) (PAMAM) has been found to be an effective carrier for the delivery of miR-7 into glioma cells owing to its low toxicity, high solubilization, and delayed release [49]. A recent study demonstrated the successful delivery of tumor suppressor miRNA (*let-7a*)-conjugated magnetic NPs to brain cells followed by magnetic hyperthermia. In another study, PLGA NPs encapsulating antisense miR-21 were found to be effective in the delivery and sustained silencing of miR-21 function in glioblastoma cells [50]. Mesoporous silica NPs containing polyarginine-peptide nucleic acid (R8-PNA) conjugates targeting miR221 were used to treat temozolomide (TMZ)-resistant glioma cells. These NPs, combined with TMZ treatment, led to a significant increase in apoptosis [51].

### miRNA-mediated sensitization therapeutics

Recently, the combination treatment of miRNA therapeutics with small-molecule anticancer drugs has received much attention because of its superior therapeutic benefit (Figure 2). This approach has many advantages over conventional therapies, such as reverting the EMT, inhibiting drug resistance build-up, promoting apoptosis and autophagy, suppressing tumor angiogenesis, and inhibiting the expression of efflux transporters, such as P-glycoprotein [52]. By actively targeting oncogenic miRNAs using an anti-miR system or restoring lost tumor suppressor miRNAs, it is possible to sensitize cells to chemotherapeutic drugs. This treatment modality resulted in smaller tumor nodules *in vivo*, which are less likely to show tumor relapse. Co-delivery of miRNA/siRNA along with chemotherapeutic drugs is recommended because it has additive or synergistic effects. Chemotherapeutic drugs can inhibit cancer growth and proliferation but, over a period of time, cells acquire resistance against these drugs because of the increased expression of efflux transporters and antiapoptotic signaling. The miRNA/siRNA platform helps to overcome drug resistance by directly targeting efflux transporter expression and antiapoptotic signaling, thereby sensitizing cancer cells to chemotherapeutic drugs [53]. This co-delivery system is an



exciting platform that holds promise as a better therapeutic modality for treating cancer cells and, thus, requires further investigation. Another study using a dual miRNA combination of miR-21 and miR-10b in triple-negative breast cancer showed promising outcomes for miRNA combination therapies with drugs or with other miRNAs [20]. A recent study demonstrated that lipid NP-loaded miR-34a with paclitaxel induced increased anticancer effects compared with paclitaxel or miRNA alone [54]. miR-205 is known to sensitize pancreatic cancer cells to gemcitabine by targeting chemoresistance markers (i.e., OCT3/4, CD44, and Tubulin  $\beta$ 3) [55]. Gemcitabine-miR-205 conjugated micelles showed a highly significant reduction in tumor volume compared with gemcitabine alone in an *in vivo* pancreatic cancer model, thereby suggesting a synergistic or additive effect of the combination treatment on tumor cells [56]. miR-34a directly targets Notch-1 signaling in breast cancer, thereby inhibiting cell proliferation, invasion, and chemoresistance [57]. Dox conjugated to miR-34a HA-CS NPs not only targeted breast cancer cell migration by inhibiting Notch-1 signaling, but also sensitized cells to Dox by suppressing Dox-mediated activation of Bcl-2 expression at both the protein and transcriptome levels [57]. miR-21 is known to modulate sensitivity to chemotherapeutic drugs [58]. Co-delivery of an anti-miRNA system with chemotherapeutic drug also holds promise as an improved treatment modality. miR-21 has been proven to be an oncogenic miRNA in various types of cancer, and suppresses PTEN expression, thus promoting Akt-mediated activation of Bcl-2 signaling and inducing chemoresistance in cancer cells [59]. Co-delivery of miR-21 inhibitor conjugated to Dox encapsulated in a star-branched copolymer comprising poly(lactic acid) and poly(dimethylaminoethyl methacrylate) showed excellent anticancer efficacy. Tumor volume in glioma cells decreased by ninefold compared with control, suggesting a promising treatment approach combining gene delivery and chemotherapeutic drugs [60]. miR-200c targets class III beta-tubulin and CD44, improves the sensitivity of cancer cells to chemotherapeutic drugs, and reverts EMT by increasing E-cadherin expression [61,62]. Gelatinase-stimuli NPs for co-delivery of miR-200c and Dox in cancer stem cells (CSC) resulted in a 75% decrease in tumor volume compared with control, again suggesting a synergistic effect of combination treatment [63]. Development of multidrug resistance in breast cancer cells occurs when the miR-21-mediated signaling pathway enhances expression of efflux transporters, such as P-glycoprotein, which are then overexpressed in cancer cells [64,65]. Graphene NPs have excellent physical and mechanical properties. It was shown that adriamycin and miR-21 inhibitor encapsulation in graphene NPs had more pronounced antiproliferative effects on adriamycin-resistant MCF7 breast cancer cells [23]. Similarly, co-delivery of miR-21 inhibitor with 5-fluorouracil (5-FU) using a poly(amido amine) dendrimer showed an enhanced cytotoxic effect compared with 5-FU alone in glioblastoma cells [66]. Delivery of anti-miR-21 with poly(L-lysine)-modified PEI NPs breast cancer cells increased cell cycle arrest in G1 phase, enhanced PDCD4 expression (a direct target of miR-21), and led to apoptosis by increased expression of caspase-3. Furthermore, it decreased the IC<sub>50</sub> of Dox from 0.585 to 0.415 Mg/ml and that of cisplatin from 1.051 to 0.940 Mg/ml, showing the synergistic effect of this anti-miR21 and chemotherapeutic drug treatment [67].

## Targeted drug delivery system

A possible solution to the problem of cell-specific delivery of therapeutic miRNAs/anti-miRNAs is the utilization of targeted miRNA mimics. The problem with NP-mediated miRNA and/or drugs is that uptake by cancer cells is not specific; however, this can be circumvented utilizing targeted approaches by coating the surface of NPs with specific antibodies or ligands against proteins that are specifically expressed in cancer cells. The targeted delivery of curcumin (a natural product) was shown in C4-2 prostate cancer cell-derived xenograft tumors using PLGA NPs conjugated with I-131-labeled PSMA antibody [68,69]. These results showed significantly reduced prostate tumor burden, and the efficient delivery of curcumin to targeted prostate tumors with reduced or no uptake by other organs. This novel targeted PSMA delivery system can be used to co-deliver miRNAs and chemotherapeutic drugs to prostate cancer cells in a specific manner without any adverse effects. PSMA ligand-conjugated polymeric micelles have also been used to target prostate cancer cells. Transferrin-coated NPs have shown an excellent ability to pass through the blood-brain barrier and showed increased cytotoxic effects with zoledronic acid compared with free zoledronic acid in glioblastoma cells [70]. Folate receptors are highly expressed in breast cancer cells and NPs conjugated to the folate receptor for delivery of siRNA led to the specific uptake of NPs by breast cancer cells and the efficient delivery of siRNA to the cancer cells [71]. Aptamer-mediated delivery of short RNA therapeutics in cancer cells [72] has been studied, with promising results, and this system can be further enhanced by aptamer-conjugated drug NPs encapsulating short RNA therapeutics and chemotherapeutic drugs for enhanced cytotoxic activity.

These examples show that the targeted delivery of short RNA therapeutics combined with chemotherapeutic drugs not only increases uptake by cancer cells specifically, but also inhibits chemoresistance in cancer cells and enhances their cytotoxic effects, suggesting a synergistic effect of combinational therapy. Interleukin (IL)-10 is an important immunoregulatory cytokine and has an important role in T regulatory cell function [73]. Let-7b directly suppresses IL-10 expression in T cells and expression of let-7b regulates tumor-associated macrophages (TAMs) and tumor infiltrating DCs (TIDCs), leading to increased immune responses against the cancer cells [74]. Conjugation of let-7b miRNA to mannose moieties (TAMs and TIDCs express high levels of mannose receptors) and pH-responsive PEG-histamine-modified alginate, which disintegrates in acidic microenvironments, led to the targeted delivery of let-7b. This nanocomplex formulation showed improved survivability in tumor-bearing mice, with nearly 50% of let-7b-treated mice still alive 50 days after the start of treatment. In addition, this formulation resulted in decreased tumor weight and volume along with decreased levels of M2 macrophage markers, with a subsequent increase in M1-specific gene (*iNOS*) and decreased expression of TIDCs markers, such as CD40 and CD80 [74]. A miRNA nanobeacon constructed with HA and miR-34a efficiently targeted cancer cells and endocytosis through the CD44 receptor, which was observed both *in vitro* and *in vivo* [75] (Figure 3). Such specific targeting would improve therapeutic outcomes. A future goal would be to construct a unique nanoplatform that has inbuilt therapeutic components in addition to miRNAs, and a specific targeted moiety to specifically to kill or eradicate cancer cells.

## Concluding remarks

The successful delivery of miRNAs to cancer cells is a major hurdle in cancer therapeutics. In this review, we have focused on various advanced nanoformulations and new methodologies for the successful delivery of miRNAs to tumor cells. Via these complexation, encapsulation, and conjugation nanotechnology strategies, miRNAs can be delivered that target the tumor in passive, active, and stimuli-responsive ways. Furthermore, because of the high fibrosis and heterogeneity of tumor tissues, a single theranostic nanoformulation with simultaneous therapeutic and imaging capabilities is of current interest. In addition, nanosystems have shown reduced systemic toxicity, which has been an important concern with earlier conventional transfection systems.

## References

1. Chi Y, Zhou D. MicroRNAs in colorectal carcinoma – from pathogenesis to therapy. *J. Exp. Clin. Cancer Res.* 2016; 35:43. [PubMed: 26964533]
2. Bartel DP. MicroRNAs: target recognition and regulatory functions. *Cell.* 2009; 136:215–233. [PubMed: 19167326]
3. Ushakov K, et al. MicroRNAs in sensorineural diseases of the ear. *Front. Mol. Neurosci.* 2013; 6:52. [PubMed: 24391537]
4. Heman-Ackah SM, et al. RISC in PD: the impact of microRNAs in Parkinson's disease cellular and molecular pathogenesis. *Front. Mol. Neurosci.* 2013; 6:40. [PubMed: 24312000]
5. Zhang Y, et al. Progress in microRNA delivery. *J. Control. Release.* 2013; 172:962–974. [PubMed: 24075926]
6. Juliano R, et al. Biological barriers to therapy with antisense and siRNA oligonucleotides. *Mol. Pharm.* 2009; 6:686–695. [PubMed: 19397332]
7. Esposito CL, et al. Multifunctional aptamer–miRNA conjugates for targeted cancer therapy. *Mol. Ther.* 2014; XX:YYY–ZZZ. DE2.
8. Samal SK, et al. Cationic polymers and their therapeutic potential. *Chem. Soc. Rev.* 2012; 41:7147–7194. [PubMed: 22885409]
9. Thomas M, et al. PEI-complexed LNA antiseeds as miRNA inhibitors. *RNA Biol.* 2012; 9:1088–1098. [PubMed: 22894918]
10. Schade A, et al. Innovative strategy for microRNA delivery in human mesenchymal stem cells via magnetic nanoparticles. *Int. J. Mol. Sci.* 2013; 14:10710–10726. [PubMed: 23702843]
11. Park J, et al. Quantum dots in an amphiphilic polyethyleneimine derivative platform for cellular labeling, targeting, gene delivery, and ratiometric oxygen sensing. *ACS Nano.* 2015; 9:6511–6521. [PubMed: 26057729]
12. Hwang do W, et al. A brain-targeted rabies virus glycoprotein-disulfide linked PEI nanocarrier for delivery of neurogenic microRNA. *Biomaterials.* 2011; 32:4968–4975. [PubMed: 21489620]
13. Bozzuto G, Molinari A. Liposomes as nanomedical devices. *Int. J. Nanomedicine.* 2015; 10:975–999. [PubMed: 25678787]
14. Goonoo N, et al. Naltrexone: a review of existing sustained drug delivery systems and emerging nano-based systems. *J. Control. Release.* 2014; 183:154–166. [PubMed: 24704710]
15. Hola K, et al. Tailored functionalization of iron oxide nanoparticles for MRI, drug delivery, magnetic separation and immobilization of biosubstances. *Biotechnol. Adv.* 2015; XX:YYY–ZZZ. DE3.
16. Guo S, Huang L. Nanoparticles containing insoluble drug for cancer therapy. *Biotechnol. Adv.* 2014; 32:778–788. [PubMed: 24113214]
17. Deng X, et al. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. *Biomaterials.* 2014; 35:4333–4344. [PubMed: 24565525]

18. Wang S, et al. Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy. *Nanomedicine*. 2016; 12:411–420. [PubMed: 26711968]
19. Bhargava-Shah A, et al. Orlistat and antisense-miRNA-loaded PLGA-PEG nanoparticles for enhanced triple negative breast cancer therapy. *Nanomedicine*. 2016; 11:235–247. [PubMed: 26787319]
20. Devulapally R, et al. Polymer nanoparticles mediated codelivery of anti-miR-10b and anti-miR-21 for achieving triple negative breast cancer therapy. *ACS Nano*. 2015; 9:2290–2302. [PubMed: 25652012]
21. Hu QL, et al. Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC-1 xenograft model. *Biomaterials*. 2013; 34:2265–2276. [PubMed: 23298779]
22. Geng Y, et al. Cellular delivery of quantum dot-bound hybridization probe for detection of intracellular pre-microRNA using chitosan/poly(gamma-glutamic acid) complex as a carrier. *PLoS ONE*. 2013; 8:e65540. [PubMed: 23762388]
23. Zhi F, et al. Functionalized graphene oxide mediated adriamycin delivery and miR-21 gene silencing to overcome tumor multidrug resistance *in vitro*. *PLoS ONE*. 2013; 8:e60034. [PubMed: 23527297]
24. Ohno S, et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. *Mol. Ther*. 2013; 21:185–191.
25. Chen WY, et al. MicroRNA-34a regulates WNT/TCF7 signaling and inhibits bone metastasis in Ras-activated prostate cancer. *Oncotarget*. 2014; XX:YYY–ZZZ. DE4.
26. Gaur S, et al. Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. *Oncotarget*. 2015; 6:29161–29177. [PubMed: 26313360]
27. Alhasan AH, et al. Exosome encased spherical nucleic acid gold nanoparticle conjugates as potent microRNA regulation agents. *Small*. 2014; 10:186–192. [PubMed: 24106176]
28. Kojima K, et al. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. *Prostate*. 2010; 70:1501–1512. [PubMed: 20687223]
29. Ghosh R, et al. A gold nanoparticle platform for the delivery of functional microRNAs into cancer cells. *Biomaterials*. 2013; 34:807–816. [PubMed: 23111335]
30. Zhang T, et al. A prostate cancer-targeted polyarginine-disulfide linked PEI nanocarrier for delivery of microRNA. *Cancer Lett*. 2015; 365:156–165. [PubMed: 26054847]
31. Cheng RF, et al. MicroRNA-506 is up-regulated in the development of pancreatic ductal adenocarcinoma and is associated with attenuated disease progression. *Chin. J. Cancer*. 2016; 35:64. [PubMed: 27371108]
32. Yang W, et al. MiR-221 promotes Capan-2 pancreatic ductal adenocarcinoma cells proliferation by targeting PTEN-Akt. *Cell. Physiol. Biochem*. 2016; 38:2366–2374. [PubMed: 27230035]
33. Xu Q, et al. miR-221/222 induces pancreatic cancer progression through the regulation of matrix metalloproteinases. *Oncotarget*. 2015; 6:14153–14164. [PubMed: 25883224]
34. Khan S, et al. MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer. *Oncotarget*. 2014; 5:7599–7609. [PubMed: 25277192]
35. Setua S, et al. Restitution of tumor suppressor microRNA-145 using magnetic nanoformulation for pancreatic cancer therapy. *J. Gastrointest. Surg*. 2016; XX:YYY–ZZZ. DE5.
36. Conde J, et al. Gold-nanobeacons for simultaneous gene specific silencing and intracellular tracking of the silencing events. *Biomaterials*. 2013; 34:2516–2523. [PubMed: 23312904]
37. Arora S, et al. Synthesis, characterization, and evaluation of poly (D,L-lactide-co-glycolide)-based nanoformulation of miRNA-150: potential implications for pancreatic cancer therapy. *Int. J. Nanomedicine*. 2014; 9:2933–2942. [PubMed: 24971005]
38. Chung WM, et al. MicroRNA-21 promotes the ovarian teratocarcinoma PA1 cell line by sustaining cancer stem/progenitor populations *in vitro*. *Stem Cell Res Ther*. 2013; 4:88. [PubMed: 23890123]
39. Cubillos-Ruiz JR, et al. Reprogramming tumor-associated dendritic cells *in vivo* using miRNA mimetics triggers protective immunity against ovarian cancer. *Cancer Res*. 2012; 72:1683–1693. [PubMed: 22307839]

40. Seviour EG, et al. Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. *Oncogene*. 2016; 35:691–701. [PubMed: 25639871]
41. Xue W, et al. Small RNA combination therapy for lung cancer. *Proc. Natl. Acad. Sci. U. S. A.* 2014; 111:E3553–E3561. [PubMed: 25114235]
42. Xiao Z, et al. A small-molecule modulator of the tumor-suppressor miR34a inhibits the growth of hepatocellular carcinoma. *Cancer Res.* 2014; 74:6236–6247. [PubMed: 25217526]
43. Daige CL, et al. Systemic delivery of a miR34a mimic as a potential therapeutic for liver cancer. *Mol. Cancer Ther.* 2014; 13:2352–2360. [PubMed: 25053820]
44. Shi R, et al. Effects of miR-200c on the migration and invasion abilities of human prostate cancer Du145 cells and the corresponding mechanism. *Front. Med.* 2014; XX:YYY–ZZZ. DE6.
45. Cortez MA, et al. Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer. *Mol Ther.* 2014; 22:1494–1503. [PubMed: 24791940]
46. Esposito CL, et al. Multifunctional aptamer-miRNA conjugates for targeted cancer therapy. *Mol. Ther.* 2014; 22:1151–1163. [PubMed: 24441398]
47. Wu DW, et al. c-Myc suppresses microRNA-29b to promote tumor aggressiveness and poor outcomes in non-small cell lung cancer by targeting FHIT. *Oncogene*. 2014; XX:YYY–ZZZ. DE7.
48. Wu Y, et al. Therapeutic delivery of microRNA-29b by cationic lipoplexes for lung cancer. *Mol. Ther. Nucleic Acids.* 2013; 2:e84. [PubMed: 23591808]
49. Liu X, et al. Poly(amido amine) is an ideal carrier of miR-7 for enhancing gene silencing effects on the EGFR pathway in U251 glioma cells. *Oncol. Rep.* 2013; 29:1387–1394. [PubMed: 23404538]
50. Ananta JS, et al. Nanoparticle-Delivered Antisense MicroRNA-21 Enhances the Effects of Temozolomide on Glioblastoma Cells. *Molecular Pharmaceutics.* 2015; 12:4509–4517. [PubMed: 26559642]
51. Bertucci A, et al. Combined delivery of temozolomide and anti-miR221 PNA using mesoporous silica nanoparticles induces apoptosis in resistant glioma cells. *Small.* 2015; 11:5687–5695. [PubMed: 26395266]
52. Dai X, Tan C. Combination of microRNA therapeutics with small-molecule anticancer drugs: mechanism of action and co-delivery nanocarriers. *Adv. Drug Deliv. Rev.* 2014; XX:YYY–ZZZ. DE8.
53. Gandhi NS, et al. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. *J. Control. Release.* 2014; 194c:238–256.
54. Shi S, et al. Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression. *J. Control. Release.* 2014; 194c:228–237.
55. Singh S, et al. miRNA profiling in pancreatic cancer and restoration of chemosensitivity. *Cancer Lett.* 2013; 334:211–220. [PubMed: 23073476]
56. Mittal A, et al. Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer. *Biomaterials.* 2014; 35:7077–7087. [PubMed: 24836307]
57. Park EY, et al. Targeting of miR-34a-NOTCH1 axis reduced breast cancer stemness and chemoresistance. *Cancer Res.* 2014; XX:YYY–ZZZ. DE9.
58. Hatley ME, et al. Modulation of K-Ras-dependent lung tumorigenesis by microRNA-21. *Cancer Cell.* 2010; 18:282–293. [PubMed: 20832755]
59. Ou H, et al. Activation of miR-21 by STAT3 induces proliferation and suppresses apoptosis in nasopharyngeal carcinoma by targeting PTEN gene. *PLoS ONE.* 2014; 9:e109929. [PubMed: 25365510]
60. Qian X, et al. Star-branched amphiphilic PLA-b-PDMAEMA copolymers for co-delivery of miR-21 inhibitor and doxorubicin to treat glioma. *Biomaterials.* 2014; 35:2322–2335. [PubMed: 24332459]
61. Dykxhoorn DM. MicroRNAs and metastasis: little RNAs go a long way. *Cancer Res.* 2010; 70:6401–6406. [PubMed: 20663901]
62. Cochrane DR, et al. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. *Mol. Cancer Ther.* 2009; 8:1055–1066. [PubMed: 19435871]


63. Liu Q, et al. Targeted delivery of miR-200c/DOC to inhibit cancer stem cells and cancer cells by the gelatinases-stimuli nanoparticles. *Biomaterials*. 2013; 34(29):7191–7203. [PubMed: 23806972]
64. MacDiarmid JA, et al. Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. *Nat. Biotechnol.* 2009; 27:643–651. [PubMed: 19561595]
65. Pan F, et al. Prognostic and clinicopathological significance of microRNA-21 overexpression in breast cancer: a meta-analysis. *Int. J. Clin. Exp. Pathol.* 2014; 7:5622–5633. [PubMed: 25337203]
66. Ren Y, et al. Co-delivery of as-miR-21 and 5-FU by poly(amidoamine) dendrimer attenuates human glioma cell growth *in vitro*. *J. Biomater. Sci. Polym. Ed.* 2010; 21:303–314. [PubMed: 20178687]
67. Gao S, et al. miRNA oligonucleotide and sponge for miRNA-21 inhibition mediated by PEI-PLL in breast cancer therapy. *Acta Biomater.* 2015; 25:184–193. [PubMed: 26169933]
68. Yallapu MM, et al. Therapeutic applications of curcumin nanoformulations. *AAPS J.* 2015; 17:1341–1356. [PubMed: 26335307]
69. Yallapu MM, et al. Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer. *Biomaterials*. 2014; 35:8635–8648. [PubMed: 25028336]
70. Porru M, et al. Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid. *Oncotarget*. 2014; 5:10446–10459. [PubMed: 25431953]
71. Li H, et al. Dual MMP7-proximity-activated and folate receptor-targeted nanoparticles for siRNA delivery. *Biomacromolecules*. 2014; XX:YYY–ZZZ. DE10.
72. Esposito CL, et al. Aptamer-mediated selective delivery of short RNA therapeutics in cancer cells. *J. RNAi Gene Silencing*. 2014; 10:500–506. [PubMed: 25414727]
73. Chen X, et al. CD4+CD25+ regulatory T cells in tumor immunity. *Int. Immunopharmacol.* 2016; 34:244–249. [PubMed: 26994448]
74. Huang Z, et al. Targeted delivery of let-7b to reprogramme tumor-associated macrophages and tumor infiltrating dendritic cells for tumor rejection. *Biomaterials*. 2016; 90:72–84. [PubMed: 26994345]
75. Kim E, et al. Consecutive targetable smart nanoprobe for molecular recognition of cytoplasmic microRNA in metastatic breast cancer. *ACS Nano*. 2012; 6:8525–8535. [PubMed: 22947044]
76. Ma S, et al. E-selectin-targeting delivery of microRNAs by microparticles ameliorates endothelial inflammation and atherosclerosis. *Sci. Rep.* 2016; 6:22910. [PubMed: 26956647]
77. Chien Y, et al. Synergistic effects of carboxymethyl-hexanoyl chitosan, cationic polyurethane-short branch PEI in miR122 gene delivery: accelerated differentiation of iPSCs into mature hepatocyte-like cells and improved stem cell therapy in a hepatic failure model. *Acta Biomater.* 2015; 13:228–244. [PubMed: 25463491]
78. Costa PM, et al. MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: a new multimodal gene therapy approach for glioblastoma. *J. Control. Release*. 2015; 207:31–39. [PubMed: 25861727]
79. Wu Y, et al. Selective targeting of alveolar type II respiratory epithelial cells by anti-surfactant protein-C antibody-conjugated lipoplexes. *J. Control. Release*. 2015; 203:140–149. [PubMed: 25687308]
80. Lee HY, et al. Targeted delivery of let-7a microRNA encapsulated ephrin-A1 conjugated liposomal nanoparticles inhibit tumor growth in lung cancer. *Int. J. Nanomedicine*. 2013; 8:4481–4494. [PubMed: 24293999]
81. Liu XQ, et al. Targeted delivery of antisense inhibitor of miRNA for antiangiogenesis therapy using cRGD-functionalized nanoparticles. *Mol. Pharm.* 2011; 8:250–259. [PubMed: 21138272]
82. Wang X, et al. Targeted delivery of tumor suppressor microRNA-1 by transferrin-conjugated lipopolyplex nanoparticles to patient-derived glioblastoma stem cells. *Curr. Pharm. Biotechnol.* 2014; 15:839–846. [PubMed: 25374033]
83. Huang X, et al. Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. *Clin. Cancer Res.* 2013; 19:2355–2367. [PubMed: 23493348]

84. Zhang M, et al. Lactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma. *J. Control. Release.* 2013; 168:251–261. [PubMed: 23567045]
85. Yuan Y, et al. Glutathione-mediated release of functional miR-122 from gold nanoparticles for targeted induction of apoptosis in cancer treatment. *J. Nanosci. Nanotechnol.* 2014; 14:5620–5627. [PubMed: 25935978]
86. Tivnan A, et al. Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. *PLoS ONE.* 2012; 7:e38129. [PubMed: 22662276]
87. Devalliere J, et al. Sustained delivery of proangiogenic microRNA-132 by nanoparticle transfection improves endothelial cell transplantation. *FASEB J.* 2014; 28:908–922. [PubMed: 24221087]
88. Yu Y, et al. A tumor-specific microRNA recognition system facilitates the accurate targeting to tumor cells by magnetic nanoparticles. *Mol. Ther. Nucleic Acids.* 2016; 5:e318. [PubMed: 27138178]
89. Pang Y, et al. Fe(3)O(4)@Ag magnetic nanoparticles for microRNA capture and duplex-specific nuclease signal amplification based SERS detection in cancer cells. *Biosens. Bioelectron.* 2016; 79:574–580. [PubMed: 26749099]
90. Lellouche E, et al. MagRET nanoparticles: an iron oxide nanocomposite platform for gene silencing from microRNAs to long noncoding RNAs. *Bioconjug. Chem.* 2015; 26:1692–1701. [PubMed: 26056709]
91. Sun Z, et al. *In vivo* multimodality imaging of miRNA-16 iron nanoparticle reversing drug resistance to chemotherapy in a mouse gastric cancer model. *Nanoscale.* 2014; 6:14343–14353. [PubMed: 25327162]


**Highlights**

- MicroRNAs play a major role in cancer
- Several clinical trials with microRNA are reported for cancer treatment
- Delivery of microRNA encounters several challenges
- We report successful microRNA nano-mediated delivery for the treatment of cancer






**Figure 1.** [DE11]Scientific evidence and nano-based delivery of miRNAs for cancer therapeutics. **(A)** Publications reporting miRNA (green bars) and miRNA delivery (red bars in insert) using nanoparticle (NP) formulations from 2005 to July 2016. Data was collected from PubMed on July 26, 2016. **(B)** Structural differences in nanoparticle formulations used for miRNA delivery. (i) Polyethyleneimine (PEI) or cationic polymer-based nanoassemblies; (ii) liposomal formulations; (iii) polymer micelles; (iv) polymer NPs; (v) metal or magnetic NPs; and (vi) dendrimer-based formulations. **(C)** Possible routes of miRNA uptake mechanisms in cells: clathrin, caveolin, and receptor-mediated endocytosis. The proton sponge effect leads to the release of miRNAs from NPs.



**Figure 2.** [DE12]miRNA-mediated chemosensitization of cancer cells for improved therapeutics. Schematic representation: Step 1: loading of nanoparticles (NPs) with miRNA and drug molecules. Step 2: antibody conjugation reaction for targeted delivery; Step 3: targeted binding and intracellular release of miRNA induces chemosensitization; and Step 4: drug release promotes apoptosis in cancer cells.



**Figure 3.** Hyaluronic acid (HA) conjugation offers superior targeted delivery of miRNAs in breast cancer cells. **(A)** Schematic representation of a miR-34a-targeted nanoformulation preparation and *in vitro* specific targeting of triple-negative breast cancer cells. **(B)** *In vivo* whole-mice imaging of miR-34a nanoparticles (NPs) in an orthotopic breast cancer mouse model at different time points after intravenous injection. **(C)** Photon intensity of tumor region after injection of NPs. **(D)** *Ex vivo* excised tumor tissue exhibiting superior targeting potential of HA-conjugated NPs. Reproduced, with permission, from [72].

**Table 1**

Surface modification of NPs facilitates miRNA binding and successful drug delivery

Nanoformulation	Modification	miRNA	Refs
PEI/poly( <i>L</i> -lysine)	HA	miR-542-3p	[18]
	E-selectin	miR-146a/miR-181b	[76]
	Polyarginine	miR-145	[30]
	Carboxymethyl-hexanoyl CS	miR-122	[77]
	Rabies virus glycoprotein	miR-124a	[12]
Liposomes	Chlorotoxin	miR-21	[78]
	Surfactant protein C	miR-486	[79]
	Ephrin-A1	Let-7a	[80]
	Cyclic RGD	miR-296	[81]
	Transferrin	miR-1	[82]
	Transferrin	miR-29b	[83]
	<i>N</i> -lactobionyl-dioleoyl-phosphatidylethanolamine	miR-155	[84]
Gold NPs	Folic acid	miR-122	[85]
PEG-peptide-poly( $\epsilon$ -caprolactone) copolymer NPs	Gelatinase	miR-200c	[63]
Silica NPs	GD2	miR-34a	[86]
PLGA	Cyclic RGD	miR-132	[87]
	uPA	miR-10b and miR21	[20]
Magnetic NPs	PEI	miR-145/9/21	[88]
	Cy3-DNA probe	Let-7	[89]
	Lanthanide cations	miR-99a/486/21	[90]
	PEG	miR-16	[91]